Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 4Neoplasm Metastasis 3Melanoma 3Head and Neck Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Esophageal Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1NSCLC 1Meningeal Carcinomatosis 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Squamous Cell Carcinoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 6Nivolumab 5cemiplimab 3Photochemotherapy 3Ipilimumab 3Vemurafenib 2Hsp90 inhibitor KU757 2tozuleristide 1toripalimab 1tislelizumab 1spartalizumab 1small molecule inhibitor THX-B 1poly ICLC 1montanide ISA 51 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cobimetinib 1cc-486 1brodalumab 1avelumab 1atezolizumab 1Ultraviolet Rays 1Tumor Necrosis Factor-alpha 1Sunscreening Agents 1Sugars 1SUB1 protein, human 1Radiotherapy 1Propranolol 1Poly I-C 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Skin Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡